BC
AIMT

Brinker Capital’s Aimmune Therapeutics AIMT Stock Holding History

Brinker Capital’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$690K Buy
41,298
+1,033
+3% +$17.5K 0.02% 616
2020
Q1 		$581K Sell
40,265
-1,838
-4% -$47K 0.02% 594
2019
Q4 		$1.41M Buy
42,103
+16,223
+63% +$454K 0.04% 405
2019
Q3 		$542K Buy
+25,880
New +$528K 0.02% 678

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Brinker Capital's AIMT Position: Q2 2020 in Review

Brinker Capital increased its Aimmune Therapeutics (AIMT) stake by 2.6% in Q2 2020, buying an estimated $17.5K and bringing the position to 41,298 shares worth $690K. The position accounts for 0.02% of the portfolio, ranked #616.

Brinker Capital first reported a position in AIMT in Q3 2019 and has held it in 4 quarters since. The position peaked at $1.41M in Q4 2019. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

  • Brinker Capital held 41,298 shares of Aimmune Therapeutics worth $690K as of Q2 2020.
  • Brinker Capital bought 1,033 Aimmune Therapeutics shares in Q2 2020, an estimated $17.5K.
  • Aimmune Therapeutics made up 0.02% of Brinker Capital's portfolio in Q2 2020, its #616 holding.
  • Brinker Capital first reported a position in Aimmune Therapeutics in Q3 2019 and has held it in 4 quarters since.
  • Brinker Capital's Aimmune Therapeutics position peaked at $1.41M in Q4 2019.
  • 165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on Brinker Capital's 13F filing for Q2 2020, filed 30 Jul 2020.